

ASX Announcement

31 August 2026

BCAL Diagnostics to host ‘Meet the CEO’ - FY26 Results webinar

BCAL Diagnostics Limited (ASX: BDX, BCAL or Company) advises that Chief Executive Officer Anne-Louise Arnett and Chair Jayne Shaw will host a ‘Meet the CEO’ - FY26 Results webinar on:

Thursday, 3 September 2026 at 1pm (AEST).

The session will provide investors with an overview of BCAL’s FY26 results, recent operational and commercial progress and the Company’s priorities for the year ahead, followed by an opportunity for investors to ask questions.

To attend, please register at:

https://zoom.us/webinar/register/WN_pv6hgNkASbWJEOE0CVIRKg

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Anne-Louise Arnett
Chief Executive Officer
aarnett@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST*plus*™ as a ‘rule-out’ test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST*plus*™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.